# Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

> **NCT00096486** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 74 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00096486
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2016-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096486, "Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00096486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*